# A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

> **NCT06158854** · PHASE1,PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 76 (estimated)

## Conditions studied

- Immunoglobulin Light Chain (AL) Amyloidosis

## Interventions

- **DRUG:** ABBV-383 (Etentamig)

## Key facts

- **NCT ID:** NCT06158854
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2028-02
- **Final completion:** 2031-08
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06158854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06158854, "A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT06158854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*